Quoin says EMA grants orphan drug designation for QRX003 in peeling skin syndrome
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. Status supports protocol guidance, fee reductions, EU grant access; provides 10-year EU market exclusivity upon approval. First formal clinical trial in Peeling Skin Syndrome remains on track to start before year-end.